Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
CDK1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CDK1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of CDK1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD46 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD46 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of CD46 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CDK15 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CDK15 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of CDK15 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CDK11B Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CDK11B Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of CDK11B sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CATSPERD Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CATSPERD Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of CATSPERD sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CAMK1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CAMK1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of CAMK1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CAMKV Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CAMKV Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of CAMKV sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
BRSK1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
BRSK1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of BRSK1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CAMK4 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CAMK4 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of CAMK4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CAMK1G Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CAMK1G Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of CAMK1G sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
BMP2K Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
BMP2K Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of BMP2K sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
BRI3 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
BRI3 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of BRI3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →